Prognostic Value of miRNA-155 Expression in B-Cell Non-Hodgkin Lymphoma

摘要

Objective: MicroRNA-155 ( miRNA-155) resides within the B-cellintegration cluster gene on chromosome 21. It can act either as anoncogene or as a tumor-suppressor gene, depending on the cellbackground in which miRNA-155 is performing its specific targetgene controlling function. Therefore, the aim of this study was toinvestigate miRNA-155 expression in patients with B-cell non-Hodgkin lymphoma (NHL) and its relation to disease prognosis indiffuse large B-cell lymphoma (DLBCL) patients.Materials and Methods: Reverse transcription-polymerase chainreaction assay was performed to evaluate the expression levels ofmiRNA-155 in 84 patients with newly diagnosed B-cell NHL and 15normal controls.Results: Compared with normal controls, miRNA-155 expressionwas significantly upregulated in patients. Moreover, higher levelsof miRNA-155 were associated with the presence of B symptoms,involvement of extranodal sites, and high Eastern CooperativeOncology Group (ECOG) score. Higher levels of miRNA-155 in DLBCLwere associated with non-germinal B-cell-like type, the presence of Bsymptoms, involvement of extranodal sites, and higher InternationalPrognostic Index (IPI) and ECOG scores. Only the high IPI score andhigh miRNA-155 expression indicated a higher risk of lower eventfreesurvival using multivariate Cox regression analysis. Our datademonstrated that the expression of miRNA-155 was upregulatedin newly diagnosed B-cell NHL patients. miRNA-155 is expressed ata lower level in GCB-subtype DLBCL. Low IPI score and miRNA-155expression were predictors of longer event-free survival.Conclusion: Despite contradicting literature reports, the currentfindings suggest the potential value of miRNA-155 as a biomarkerof prognosis and monitoring in B-cell NHL, and especially that of theDLBCL type.